UK's Haleon sells NRT business outside US to Dr Reddy's Laboratories for $632.55M.
UK's Haleon has agreed to sell its nicotine replacement therapy (NRT) business outside the US to Dr Reddy's Laboratories SA for $632.55 million. The portfolio includes brands such as Nicotinell, Nicabate, Habitrol, and Thrive available in gum, lozenge, and patch forms across over 30 markets. Haleon CEO Brian McNamara said the divestment is consistent with the company's strategy to become more agile and competitive.
June 26, 2024
9 Articles